Facebook
X
LinkedIn
Forward
MASH Uncovered: Essential Insights for Clinicians on Effective Screening, Risk Stratification, and Disease Management
This symposium, recorded at the 20th Annual CMHC meeting, offers an in-depth exploration of the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The program is tailored to equip primary care clinicians (PCPs) with insights into the complex interplay of cardiometabolic risk factors—such as obesity and diabetes—that contribute to disease progression. Additionally, the symposium features a powerful patient perspective, with a live participant sharing her personal journey, the challenges she encountered, and how collaborative care with her health care team led to effective disease management and improved outcomes. By encouraging the timely identification and management of MASH through the latest advancements, PCPs and other healthcare professionals can more effectively address the growing burden of this condition.
Target Audience
The educational design of this activity addresses the needs of U.S.-based primary care physicians followed by U.S.-based cardiologists, endocrinologists as well as nurse practitioners, pharmacists, and physician assistants.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain MAFLD/MASH pathogenesis and the role that cardiovascular and cardiometabolic risk factors, including obesity and diabetes, play in MASH progression to improve the identification of MASH.
- Review the importance of non-invasive tests for the timely screening, risk stratification, disease progression and when to refer intermediate- to high-risk MASH/ MASLD patients to the specialty clinics.
- Summarize recommendations from latest guidelines for treatment of MASH, including recent guidelines and consensus statements.
- Review the rationale, efficacy and safety of GLP-1 RAs for the treatment of MASH.
- List emerging and recently FDA approved MASH pharmacotherapies targeting various metabolic, inflammatory, and fibrotic pathways involved in disease progression.
- Select comprehensive treatment strategies, including lifestyle modification and obesity pharmacotherapy, and a multidisciplinary approach, to address MASH and MASLD.
Conan Tu, MD MBA (Chair)
Regional Chief of Adult Primary Care
Eastern Long Island Optum NY/NJ
New York
Karen Fitzpatrick, RN, MSN
Patient Advocate
Senior Director, Clinical Research
ECOG-ACRIN/ PrECOG
Diana Barb, MD
Clinical Associate Professor
University of Florida
Gainesville, FL
Amreen Dinani, MD, FRCPC, ABOM
Associate Professor of Medicine
Duke University Health
Durham, NC
ESTIMATED TIME TO COMPLETE ACTIVITY
1.25 hours
EDUCATIONAL GRANT SUPPORT
Multi-supported by independent educational grants from Novo Nordisk and Boehringer Ingelheim Pharmaceuticals, Inc. Held in partnership with the Global Liver Institute.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Cardiometabolic Health Congress (CMHC). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
Partners designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
Partners designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - UAN JA4008073-9999-26-059-H01-P
Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DIETITIAN CONTINUING EDUCATION
This program offers 1.25 CPEUs for dietitians.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 0.75 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from January 23, 2026 through January 23, 2027.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at [email protected]. For additional information about the accreditation of this activity, please visit https://partnersed.com
DISCLOSURES
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Barb, faculty for this educational activity, discloses the following:
- Consultant, Advisor, Speaker: Boehringer Ingelheim, Novo Nordisk
- Researcher: Boehringer Ingelheim, Inventiva
Dr. Dinani, faculty for this educational activity, discloses the following:
- Consultant, Advisor, Speaker: Madrigal Pharmaceuticals, Novo Nordisk, Petauri
- Other: Akero, 89Bio, Inventiva, NIH/NCI
Ms. Fitzpatrick has no relevant financial relationship(s) with ineligible companies to disclose.
Dr. Tu, faculty for this educational activity, discloses the following:
- Speaker, Advisory Board: Sanofi
- Speaker: Abbott, Intuity Medical, Astra Zeneca
- Advisory Board: Novo Nordisk, Insulet, Eli Lilly
- Publication Support: Bayer
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.25 ACPE Pharmacy
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC
- 1.25 CDE
- 1.25 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.